...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Antithymocyte Globulin before Allogeneic Stem Cell Transplantation for Progressive Myelodysplastic Syndrome: A Study from the French Society of Bone Marrow Transplantation and Cellular Therapy
【24h】

Antithymocyte Globulin before Allogeneic Stem Cell Transplantation for Progressive Myelodysplastic Syndrome: A Study from the French Society of Bone Marrow Transplantation and Cellular Therapy

机译：异体干细胞移植治疗进展性骨髓增生异常综合征前的抗胸腺细胞球蛋白：来自法国骨髓移植和细胞治疗学会的一项研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We investigated the impact of rabbit antithymocyte globulins (ATG) on patient outcomes after allogeneic stem cell transplantation (allo-SCT) for progressive myelodysplastic syndrome (MDS). Of the 242 consecutive patients who underwent allo-SCT for progressive MDS between October 1999 and December 2009, 93 received ATG (ATG group) at the median dose of 5mg/kg, whereas 149 patients did not (no-ATG group). Donors were sibling (n=153) or HLA-matched unrelated (n=89). Patients received blood (n=90) or marrow (n=152) grafts after either myeloablative (n=109) or reduced-intensity (n=133) conditioning. Three-year overall and event-free survival, nonrelapse mortality, relapse, and chronic graft-versus-host disease (GVHD) development were not significantly different between the 2 groups. In contrast, acute grade II to IV GVHD occurred more often in the no-ATG group (55% of the patients) than in the ATG group (27%, P<.0001). Similar results were observed with acute grade III to IV GVHD (28% and 14% in the no-ATG group and ATG group, respectively; P=.009). In multivariate analysis, after adjustment with propensity score, the absence of ATG was the strongest parameter associated with an increased risk of acute grade II to IV GVHD (hazard ratio, 2.13; 95% confidence interval, 1.35 to 3.37; P=.001]. ATG had no impact on overall and event-free survival or cumulative incidence of the relapse. In conclusion, the addition of ATG to allo-SCT conditioning did not increase the incidence of relapse of patients with progressive MDS. The incidence of acute GVHD was decreased without compromising outcomes.
机译：我们调查了进行性骨髓增生异常综合征（MDS）的异基因干细胞移植（allo-SCT）后，兔抗胸腺细胞球蛋白（ATG）对患者预后的影响。在1999年10月至2009年12月间接受allo-SCT进行进展性MDS的242例连续患者中，有93例接受中剂量5mg / kg的ATG（ATG组），而没有接受149例患者（无ATG组）。供体是兄弟姐妹（n = 153）或与HLA匹配的无关亲戚（n = 89）。患者在进行清髓处理（n = 109）或强度降低（n = 133）后接受了血液（n = 90）或骨髓（n = 152）移植。两组的三年总体生存率和无事件生存率，非复发死亡率，复发率和慢性移植物抗宿主病（GVHD）的发生率两组之间无显着差异。相比之下，no-ATG组（占患者的55％）比ATG组（占27％，P <.0001）更容易发生急性II至IV GVHD。急性III至IV级GVHD观察到相似的结果（no-ATG组和ATG组分别为28％和14％; P = .009）。在多变量分析中，用倾向得分进行调整后，ATG的缺乏是与急性II至IV级GVHD风险增加相关的最强参数（危险比，2.13; 95％置信区间，1.35至3.37; P = .001] 。ATG对总体生存率和无事件生存率或复发的累积发生率没有影响，总的来说，在allo-SCT调理中添加ATG不会增加进行性MDS患者的复发率。减少而不影响结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号